Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 839,203 shares of the biotechnology company's stock after purchasing an additional 24,132 shares during the quarter. American Century Companies Inc. owned about 1.32% of Blueprint Medicines worth $73,195,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Quarry LP purchased a new position in Blueprint Medicines during the third quarter worth $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines in the 4th quarter worth about $51,000. Asset Management One Co. Ltd. purchased a new position in shares of Blueprint Medicines during the 4th quarter worth about $88,000. Van ECK Associates Corp boosted its stake in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares during the period. Finally, Quantbot Technologies LP bought a new position in Blueprint Medicines during the 3rd quarter valued at about $108,000.

Insider Activity at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This represents a 3.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,608 shares of company stock valued at $3,319,587 over the last 90 days. Insiders own 4.21% of the company's stock.

Remove Ads

Blueprint Medicines Stock Down 1.1 %

Shares of NASDAQ BPMC traded down $1.01 during mid-day trading on Friday, reaching $88.72. 621,251 shares of the company were exchanged, compared to its average volume of 729,152. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The firm has a 50-day moving average of $98.13 and a 200 day moving average of $93.99. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BPMC. Piper Sandler boosted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Needham & Company LLC restated a "buy" rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Stephens reaffirmed an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, Scotiabank assumed coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price target on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.